Diseases that affect fewer than one in 2,000 people are considered rare. They are often chronic, have severe courses and carry the risk of permanent organ damage and deterioration for patients. More than 7,000 rare diseases are currently known to medicine.
What are the neural computations underlying social behaviour in groups? How are multi-modal cues integrated to control and switch between courtship and aggression? How does sensory processing adapt in big crowds to target the behaviourof individual members of the group?
The conventional detection of proteins by imaging employs fluorophores or antibodies directed at individual proteins. However, this methodology cannot be upscaled and employed in a high-throughput omics approach.
eHealth – the use of digital technologies in the treatment and care of patients – plays a central role for Europe and its member states. eHealth technologies offer significant opportunities for the prevention, treatment and management of diseases, especially in ageing societies. At the same time, it could help contain rising costs for the expanding use of health services.
The biodegradability of drugs was previously considered an environmental issue. Now Leuphana, together with leading pharmaceutical companies, is a partner in the EU project “Priorisation and Risk Evaluation of Medicines in the Environment” (PREMIER).
The development of cost-effective, reliable, and high-performance battery cells will be essential to strategic sectors in Europe such as the automotive industry (electro-mobility) and the electric power sector.